Products

Our products

Learn more about our product portfolio and how we’re prioritising vaccines and specialty medicines to get ahead of disease together.

Our product areas Products A-Z

Close Video

Scroll to explore

Our product areas

Vaccines

Our unrivalled vaccine portfolio targets infectious diseases at every stage of life. From adjuvants that improve vaccine effectiveness, through to mRNA technology, we use advanced technologies and collaborate with our partners to develop new, more effective vaccines that help people around the world to get ahead of disease.

Specialty medicines

As our experts seek innovative new ways to treat the human body, specialty medicines are at the forefront of our high-value pipeline of new products. We are global leaders in developing medicines for respiratory disease and HIV, and we are building our presence in other key therapy areas such as immunology and oncology.

General medicines

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. For us, this includes our medicines for inhaled respiratory, dermatology and other diseases. These vital medications are the engine room of GSK, supporting hundreds of millions of people to enjoy a better everyday quality of life.

View our product areas

Our vaccines and medicines

Getting ahead means preventing disease as well as treating it. Our R&D focus is to deliver new vaccines and medicines using the science of the immune system, human genetics and advanced technologies.

vaccines manufacturing sites - enabling a supply capability to produce and deliver 500 million vaccine doses in 2022

1.5m

doses of vaccines delivered every day

20+

vaccines, helping to protect lives from diseases including meningitis, shingles, flu, whooping cough, measles, hepatitis and human papillomavirus (HPV)

40%

of the world’s children receive a GSK vaccine each year

2.3bn

packs of medicines and doses of vaccines delivered in 2022

Explore our innovation stories

Innovation is at the very core of GSK. Discover how we’re uniting science, technology and talent to get ahead of disease together.

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics

Scientists gain ground in centuries-long malaria struggle – but more innovation is needed to stay ahead of evolving parasites

Modern technologies are doubling the odds of scientists making life-changing medical discoveries

Age-related decline in immunity: why does it matter and what can be done about it?

Vaccinations are not just for children: why adult immunisation is a health and economic necessity

‘We’re not a world of men – it's as simple as that’: how gender diversity in clinical trials improves health outcomes for women

Read our magazine

Continue to Responsibility